NovoCure Limited (NASDAQ:NVCR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
As you might know, NovoCure Limited (NASDAQ:NVCR) just kicked off its latest third-quarter results with some very strong numbers. Results overall were solid, with revenues arriving 6.1% better than analyst forecasts at US$193m. Higher revenues also resulted in substantially lower statutory losses which, at US$0.09 per share, were 6.1% smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
After the latest results, the seven analysts covering NovoCure are now predicting revenues of US$808.3m in 2027. If met, this would reflect a notable 11% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 26% to US$0.77. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$804.8m and losses of US$0.83 per share in 2027. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
View our latest analysis for NovoCure
The average price target held steady at US$26.43, seeming to indicate that business is performing in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values NovoCure at US$52.00 per share, while the most bearish prices it at US$15.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting NovoCure's growth to accelerate, with the forecast 9.0% annualised growth to the end of 2027 ranking favourably alongside historical growth of 6.3% per annum over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 7.3% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that NovoCure is expected to grow at about the same rate as the wider industry.
The Bottom Line
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for NovoCure going out to 2028, and you can see them free on our platform here..
You can also see our analysis of NovoCure's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.